Patents Assigned to National Cerebral and Cardiovascular Center
  • Publication number: 20200197446
    Abstract: The purpose of the present invention is to provide a novel medical application of pluripotent stem cells (muse cells) in regeneration medicine. The present invention provides a cell preparation and a pharmaceutical composition which are for amelioration and treatment of brain disorders resulting from fetal growth retardation, such as abnormal motor quality or abnormal neurological development, and which contain SSEA-3 positive pluripotent stem cells isolated from a mesenchymal tissue from a live body or cultured mesenchymal cells. It is assumed that this cell preparation is based on a mechanism where muse cells that are administered to objects having the disorders are engrafted on an impaired brain tissue, thereby ameliorating or treating the disorders.
    Type: Application
    Filed: June 20, 2018
    Publication date: June 25, 2020
    Applicants: National University Corporation Nagoya University, TOHOKU UNIVERSITY, NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER, Life Science Institute, Inc.
    Inventors: Yoshiaki SATO, Yuma KITASE, Shinobu SHIMIZU, Masaaki MIZUNO, Masahiro HAYAKAWA, Mari DEZAWA, Masahiro TSUJI
  • Publication number: 20200190590
    Abstract: Provided is a method for predicting probability of ischemic stroke onset. A method for predicting a risk of ischemic stroke onset, the method comprising: a detection step of detecting presence or absence of a RNF213 p.R4810K gene variant in a sample derived from a test subject who does not develop ischemic stroke; and a determination step of determining whether a probability of ischemic stroke onset of the test subject is high or not, based on the presence or absence of the RNF213 p.R4810K gene variant in the detection step, and gender information of the test subject. A genetic marker for predicting a risk of ischemic stroke onset using gender information, comprising a RNF213 p.R4810K gene variant. A biomarker for predicting a risk of ischemic stroke onset using gender information, comprising a polypeptide encoded by a RNF213 p.R4810K gene variant.
    Type: Application
    Filed: December 10, 2019
    Publication date: June 18, 2020
    Applicants: NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER, SHIMADZU CORPORATION
    Inventors: Masafumi IHARA, Shuhei OKAZAKI, Daisuke KAWAKAMI
  • Patent number: 10624555
    Abstract: A myocardial excitation complementation/visualization apparatus includes an acquiring section that acquires intracardiac electrocardiograms of a subject, the intracardiac electrocardiograms being recorded by a recording unit having a plurality of electrodes, a processing section that performs a computation for completing and visualizing a state of excitation in a myocardium of the subject based on the intracardiac electrocardiograms, and a displaying section that displays the state of excitation in the myocardium of the subject based on an output of the processing section. The processing section includes a first generating section, a correcting section, a second generating section, and a third generating section. The displaying section displays a change of the state of excitation in the myocardium of the subject based on the visualized data.
    Type: Grant
    Filed: March 15, 2016
    Date of Patent: April 21, 2020
    Assignees: SHIGA UNIVERSITY OF MEDICAL SCIENCE, NIHON KOHDEN CORPORATION, NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER
    Inventors: Takashi Ashihara, Koji Takizawa, Tatsuo Nishihara, Nobuhiro Suzuki, Yuuho Iwanaga, Akio Ota, Takeshi Tsuchiya, Kazuo Nakazawa, Shin Inada
  • Patent number: 10550153
    Abstract: To provide a peptide that selectively activates type 2 neuromedin U receptor and is chemically stable under physiological conditions. A peptide represented by Formula (1) described in the specification.
    Type: Grant
    Filed: January 19, 2018
    Date of Patent: February 4, 2020
    Assignees: TOKYO UNIVERSITY OF PHARMACY & LIFE SCIENCES, NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER, KYOTO PHARMACEUTICAL UNIVERSITY
    Inventors: Yoshio Hayashi, Kentaro Takayama, Mikiya Miyazato, Kenji Kangawa, Kenji Mori, Akira Yamamoto, Toshiyasu Sakane
  • Publication number: 20190365944
    Abstract: Provided is a use for a peptide in surface-treating a medical device or medical material to be used in contact with blood, with which it is possible to obtain a medical device or medical material that can achieve highly efficient vascular endothelialization through the use of a peptide uniquely binding to vascular endothelial cells. Also provided are: a peptide suitable for use in said surface treatment; a method for producing a medical device or medical material surfaced-treated with said peptide and to be used in contact with blood; and a surface treatment agent including said peptide, said agent to be used in surface-treating a medical device or medical material to be used in contact with blood. In the present invention, a medical device or medical material is surface-treated using a peptide that includes any one of ten specific amino acid sequences and uniquely binds to the surface of endothelial progenitor cells.
    Type: Application
    Filed: January 30, 2018
    Publication date: December 5, 2019
    Applicants: NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER, JMS CO., LTD.
    Inventors: Tetsuji YAMAOKA, Maria MUNISSO, Atsushi MAHARA, Takashi YAMAMOTO
  • Publication number: 20190343892
    Abstract: An object of the present invention is to provide a method for producing a mesenchymal stromal cell composition, comprising conveniently and aseptically separating high-purity amnion-derived MSCs by performing enzyme treatment only once. According to the present invention, the following are provided: a method for producing a mesenchymal stromal cell composition, comprising: performing enzyme treatment of an amnion with collagenase and thermolysin and/or dispase; and filtering the enzyme-treated amnion through a mesh; a method for producing a cryopreserved mesenchymal stromal cell composition; and a therapeutic agent comprising as an active ingredient the mesenchymal stromal cell composition for a disease selected from graft-versus-host disease, inflammatory bowel disease, systemic lupus erythematosus, liver cirrhosis, or radiation enteritis.
    Type: Application
    Filed: July 11, 2019
    Publication date: November 14, 2019
    Applicants: NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER, FOUNDATION FOR BIOMEDICAL RESEARCH AND INNOVATION AT KOBE, HYOGO COLLEGE OF MEDICINE, NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY, KANEKA CORPORATION
    Inventors: Kenichi YAMAHARA, Akihiko TAGUCHI, Toshihiro SOMA, Shunsuke OHNISHI, Akira KOBAYASHI
  • Patent number: 10471179
    Abstract: The present invention provides a connective tissue body formation substrate which can form a film connective tissue having a desired thickness and both surfaces in a desired surface condition without prolonging the time required for formation of the connective tissue. Specifically, two tissue formation surfaces 2a and 2b are faced with each other with a tissue formation space 3 being interposed therebetween. A slit 9 is formed in the tissue formation surface 2b so that the tissue formation space 3 communicates with an outside of the substrate. A connective tissue body formation substrate 1 is installed in an environment where a biological tissue material is present. A connective tissue intrudes into the tissue formation space 3 from the slit 9. Both surfaces of the film connective tissue are formed so as to match the substrate surface.
    Type: Grant
    Filed: November 13, 2015
    Date of Patent: November 12, 2019
    Assignee: NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER
    Inventors: Yasuhide Nakayama, Tomonori Oie, Takeshi Moriwaki
  • Patent number: 10441611
    Abstract: An object of the present invention is to provide a method for producing a mesenchymal stromal cell composition, comprising conveniently and aseptically separating high-purity amnion-derived MSCs by performing enzyme treatment only once. According to the present invention, the following are provided: a method for producing a mesenchymal stromal cell composition, comprising: performing enzyme treatment of an amnion with collagenase and thermolysin and/or dispase; and filtering the enzyme-treated amnion through a mesh; a method for producing a cryopreserved mesenchymal stromal cell composition; and a therapeutic agent comprising as an active ingredient the mesenchymal stromal cell composition for a disease selected from graft-versus-host disease, inflammatory bowel disease, systemic lupus erythematosus, liver cirrhosis, or radiation enteritis.
    Type: Grant
    Filed: August 18, 2014
    Date of Patent: October 15, 2019
    Assignees: NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER, FOUNDATION FOR BIOMEDICAL RESEARCH AND INNOVATION AT KOBE, HYOGO COLLEGE OF MEDICINE, NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY, KANEKA CORPORATION
    Inventors: Kenichi Yamahara, Akihiko Taguchi, Toshihiro Soma, Shunsuke Ohnishi, Akira Kobayashi
  • Patent number: 10398738
    Abstract: An object of the present invention is to provide a method for producing a mesenchymal stromal cell composition, comprising conveniently and aseptically separating high-purity amnion-derived MSCs by performing enzyme treatment only once. According to the present invention, the following are provided: a method for producing a mesenchymal stromal cell composition, comprising: performing enzyme treatment of an amnion with collagenase and thermolysin and/or dispase; and filtering the enzyme-treated amnion through a mesh; a method for producing a cryopreserved mesenchymal stromal cell composition; and a therapeutic agent comprising as an active ingredient the mesenchymal stromal cell composition for a disease selected from graft-versus-host disease, inflammatory bowel disease, systemic lupus erythematosus, liver cirrhosis, or radiation enteritis.
    Type: Grant
    Filed: August 18, 2014
    Date of Patent: September 3, 2019
    Assignees: NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER, FOUNDATION FOR BIOMEDICAL RESEARCH AND INNOVATION AT KOBE, HYOGO COLLEGE OF MEDICINE, NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY, KANEKA CORPORATION
    Inventors: Kenichi Yamahara, Akihiko Taguchi, Toshihiro Soma, Shunsuke Ohnishi, Akira Kobayashi
  • Patent number: 10351600
    Abstract: A peptide that enables surface treatment of a scaffold for tissue repair that makes it possible to accelerate the repair of living tissue without using a material that negatively affects the repair of living tissue, a complex containing this peptide, a scaffold for tissue repair surface treated using this peptide or this complex, a surface treatment method for a scaffold for tissue repair using this peptide or this complex, and a treatment solution or set of treatment solutions to be used in this surface treatment method. Surface treatment of a scaffold for tissue repair is conducted by combining glycosaminoglycan and a peptide containing adhesive sites and basic sites each comprising predetermined amino acid residues.
    Type: Grant
    Filed: July 28, 2017
    Date of Patent: July 16, 2019
    Assignees: National Cerebral and Cardiovascular Center, JMS Co., Ltd.
    Inventors: Tetsuji Yamaoka, Sachiro Kakinoki, Shunsuke Baba, Yoshiya Hashimoto
  • Publication number: 20190201583
    Abstract: The present invention provides a method for forming a connective tissue body, which enables extending the ranges of design values in terms of shape, dimension, etc., of the connective tissue body. This method comprises: a fat treatment step for removing fat contained in a connective tissue body, which is formed in an environment where a biological tissue material is present, from the interior of the connective tissue body while the connective tissue body is being set in a molding tool, and for causing the shape of the connective tissue body to follow the shape of the molding tool; and a bioinert solution treatment step for immersing the connective tissue body, together with the molding tool, in a bioinert solution while the connective tissue body is being shaped so as to follow the shape of the molding tool after the fat treatment step.
    Type: Application
    Filed: August 30, 2017
    Publication date: July 4, 2019
    Applicants: BIOTUBE CO., LTD., NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER
    Inventors: Yasuhide NAKAYAMA, Takeshi MORIWAKI, Tomonori OIE
  • Publication number: 20190142820
    Abstract: Provided is a drug superior for preventing and/or treating dementia. It contains a carbostyril derivative of the following formula (1) (wherein R is a cycloalkyl group, A is a lower alkyl group, and a single bond or a double bond is present between the 3-position and the 4-position of the carbostyril nucleus) and dihydroquercetin.
    Type: Application
    Filed: May 1, 2017
    Publication date: May 16, 2019
    Applicants: NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER, FOUNDATION FOR BIOMEDICAL RESEARCH AND INNOVATION AT KOBE
    Inventors: Tadamasa MATSUMOTO, Masafumi IHARA, Satoshi SAITO, Masanori FUKUSHIMA
  • Publication number: 20190083225
    Abstract: A tissue body formation device for forming a connective tissue body in an environment where a living tissue material is present is provided with: an inner member having a tissue body formation surface that serves as a surface for forming a connective tissue body; and a covering member which is provided with a covering surface that constitutes an external surface of the tissue body formation device, and that covers a part of the tissue body formation surface. The covering member further has a plurality of connection parts that connect the outer side of the tissue body formation device to the tissue body formation surface. Each of the connection parts has an opening in the covering surface. Each of the openings has a minimum dimension of at least 0.5 mm in a direction along the covering surface. The openings account for 20-40% per unit area of the covering surface.
    Type: Application
    Filed: May 11, 2017
    Publication date: March 21, 2019
    Applicants: SHINKAN KOGYO K.K., NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER
    Inventors: Yasuhide NAKAYAMA, Takeshi MORIWAKI, Tomonori OIE
  • Publication number: 20190076041
    Abstract: A myocardial excitation determining apparatus which can support the determination of excitation dynamics of the myocardium during atrial fibrillation is provided. A myocardial excitation determining apparatus has: an acquiring section 2 which acquires an intracardiac electrocardiogram of a subject; a processing section 3 which computes to produce visualized data indicating a state of excitation in the myocardium, based on the intracardiac electrocardiogram; and a determining section 4 which determines the type of excitation dynamics of the myocardium based on the visualized data.
    Type: Application
    Filed: March 14, 2017
    Publication date: March 14, 2019
    Applicants: SHIGA UNIVERSITY OF MEDICAL SCIENCE, NIHON KOHDEN CORPORATION, NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER
    Inventors: Takashi ASHIHARA, Koji TAKIZAWA, Tatsuo NISHIHARA, Nobuhiro SUZUKI, Yuuho IWANAGA, Akio OTA, Takeshi TSUCHIYA, Kazuo NAKAZAWA, Shin INADA
  • Publication number: 20190040359
    Abstract: The present disclosure aims to provide a method of efficiently manufacturing a cell mass, a cell structure, or a three-dimensional tissue body using a culturing surface coated with a temperature-responsive polymer or a temperature-responsive polymer composition. The manufacturing method of a cell mass, a cell structure, or a three-dimensional tissue body of the present disclosure includes seeding and culturing cells on a culturing surface coated with a temperature-responsive polymer or a temperature-responsive polymer composition.
    Type: Application
    Filed: January 27, 2017
    Publication date: February 7, 2019
    Applicant: NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER
    Inventors: Yasuhide NAKAYAMA, Ryosuke IWAI, Yasushi NEMOTO
  • Publication number: 20180362922
    Abstract: The object of the present invention is to provide a method for producing a cell population comprising mesenchymal stem cells having a high specific growth rate which are useful for promptly producing large amounts of cell formulations. The present invention provides a method for producing a cell population comprising mesenchymal stem cells, comprising: a step of treating a cell population comprising mesenchymal stem cells having different proliferative ability by physical stimulation or chemical stimulation, so as to select mesenchymal stem cells having relatively high proliferative ability, wherein the selected mesenchymal stem cells having relatively high proliferative ability are negative for CD106, and the expression level of a metallothionein family gene is increased in comparison to the expression level thereof in the cell population before the treatment by the physical stimulation or chemical stimulation.
    Type: Application
    Filed: October 27, 2016
    Publication date: December 20, 2018
    Applicants: KANEKA CORPORATION, NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER
    Inventors: Kenichi YAMAHARA, Yuta KITA, Keita INO, Akira KOBAYASHI
  • Publication number: 20180355296
    Abstract: The present disclosure aims to provide a cell culture container capable of easily producing large quantities of minute cellular structures. A cell culture container includes a plurality of first coated regions, on a culture surface of the cell culture container, coated by a temperature-responsive polymer or a temperature-responsive polymer composition. The surface zeta potential of the first coated regions is from 0 mV to 50 mV.
    Type: Application
    Filed: June 24, 2016
    Publication date: December 13, 2018
    Applicant: NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER
    Inventors: Yasuhide NAKAYAMA, Ryosuke IWAI, Yasushi NEMOTO
  • Publication number: 20180289278
    Abstract: A cardiac catheter inspection apparatus comprising: an acquiring section (31) which is configured to acquire a first waveform of heart beats during sinus rhythm, and an arrhythmia waveform during arrhythmia; a measuring section (31) which is configured to measure a second electrocardiogram; a first calculating section (32) which is configured to calculate correction coefficients for statistically matching the first electrocardiogram and the second electrocardiogram with each other; a waveform producing section (34) which is configured to produce a comparison waveform that functions as an object to be compared with a response waveform of pacing performed by a cardiac catheter; and a second calculating section (36) which is configured to calculate a matching rate of the response waveform and the comparison waveform.
    Type: Application
    Filed: January 5, 2016
    Publication date: October 11, 2018
    Applicants: NIHON KOHDEN CORPORATION, NATIONAL CEREBRAL & CARDIOVASCULAR CENTER
    Inventors: Kazuo NAKAZAWA, Shin INADA, Tatsuo NISHIHARA, Koji TAKIZAWA, Hiroki YUZE, Naoki KOURA
  • Patent number: 10071099
    Abstract: Provided are a novel medicament for suppressing or preventing the metastasis of a malignant tumor such as carcinoma, a novel treatment or prevention method for suppressing or preventing the metastasis of a malignant tumor, etc. The medicament comprises a non-peptidic angiotensin type 2 receptor agonist as an active ingredient. In the medicament, the non-peptidic angiotensin type 2 receptor agonist may be, for example, a sulfonyl malonamide compound. The medicament may be a medicament for use in combination with an anticancer agent and/or an antitumor agent.
    Type: Grant
    Filed: April 3, 2015
    Date of Patent: September 11, 2018
    Assignee: NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER
    Inventors: Kenji Kangawa, Hiroshi Hosoda, Takashi Nojiri
  • Patent number: 9993164
    Abstract: A monitoring apparatus includes a condition determining section which is configured to determine a condition of one of a heart, lungs, and blood vessels based on: a concentration of carbon dioxide in an expired gas which is measured by using a first sensor; and an oxygen transport parameter or a metabolic parameter which is measured by using a second sensor.
    Type: Grant
    Filed: January 23, 2015
    Date of Patent: June 12, 2018
    Assignees: NIHON KOHDEN CORPORATION, NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER
    Inventors: Masami Tanishima, Tatsuo Yoshida, Teiji Ukawa, Masafumi Kitakaze, Osamu Seguchi